DE60221875D1 - 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren - Google Patents

4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren

Info

Publication number
DE60221875D1
DE60221875D1 DE60221875T DE60221875T DE60221875D1 DE 60221875 D1 DE60221875 D1 DE 60221875D1 DE 60221875 T DE60221875 T DE 60221875T DE 60221875 T DE60221875 T DE 60221875T DE 60221875 D1 DE60221875 D1 DE 60221875D1
Authority
DE
Germany
Prior art keywords
low
pyrrolidine derivatives
hcv inhibitors
heteroaryl acyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60221875T
Other languages
English (en)
Other versions
DE60221875T2 (de
Inventor
Gianpaolo Bravi
Rossella Guidetti
David Haigh
Charles David Hartley
Peter David Howes
Deborah Lynette Jackson
Victoria Lucy Helen Lovegrove
Pritom Shah
Martin John Slater
Katrina Jane Wareing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0126440A external-priority patent/GB0126440D0/en
Priority claimed from GB0203900A external-priority patent/GB0203900D0/en
Priority claimed from GB0219321A external-priority patent/GB0219321D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60221875D1 publication Critical patent/DE60221875D1/de
Application granted granted Critical
Publication of DE60221875T2 publication Critical patent/DE60221875T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60221875T 2001-11-02 2002-10-30 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren Expired - Lifetime DE60221875T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0126440A GB0126440D0 (en) 2001-11-02 2001-11-02 Compounds
GB0126440 2001-11-02
GB0203900A GB0203900D0 (en) 2002-02-19 2002-02-19 Compounds
GB0203900 2002-02-19
GB0219321A GB0219321D0 (en) 2002-08-19 2002-08-19 Compounds
GB0219321 2002-08-19
PCT/EP2002/012176 WO2003037895A1 (en) 2001-11-02 2002-10-30 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors

Publications (2)

Publication Number Publication Date
DE60221875D1 true DE60221875D1 (de) 2007-09-27
DE60221875T2 DE60221875T2 (de) 2007-12-20

Family

ID=27256312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221875T Expired - Lifetime DE60221875T2 (de) 2001-11-02 2002-10-30 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren

Country Status (9)

Country Link
US (1) US7259163B2 (de)
EP (1) EP1440069B1 (de)
JP (1) JP2005515172A (de)
AR (1) AR037182A1 (de)
AT (1) ATE370137T1 (de)
DE (1) DE60221875T2 (de)
ES (1) ES2289161T3 (de)
TW (1) TW200302823A (de)
WO (1) WO2003037895A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211418D0 (en) * 2002-05-17 2002-06-26 Glaxo Group Ltd Compounds
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
DE602005002357T2 (de) * 2004-03-26 2008-05-29 Smithkline Beecham Corp. Als antivirale mittel geeignete 4-carboxypyrazolderivate
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090004140A1 (en) * 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PT2373172E (pt) 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376514A2 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Nukleosidanaloga
EP2376088B1 (de) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituierte-2-Amino-Purin-Nukleosid-Phosphoramidate
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
ES2655091T3 (es) 2009-12-18 2018-02-16 Ogeda Sa Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
AR082619A1 (es) 2010-08-13 2012-12-19 Hoffmann La Roche Inhibidores del virus de la hepatitis c
US20130302282A1 (en) 2010-10-26 2013-11-14 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
US9180193B2 (en) 2011-10-10 2015-11-10 Hoffmann-La Roche Inc. Antiviral compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013087743A1 (en) 2011-12-16 2013-06-20 F. Hoffmann-La Roche Ag Inhibitors of hcv ns5a
JP5982007B2 (ja) 2011-12-20 2016-08-31 リボサイエンス・エルエルシー Ｈｃｖｒｎａ複製の阻害薬としての２’，４’−ジフルオロ−２’−メチル置換されたヌクレオシド誘導体
US9708357B2 (en) 2011-12-20 2017-07-18 Riboscience, LLC 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
RU2014137052A (ru) 2012-02-24 2016-04-10 Ф.Хоффманн-Ля Рош Аг Противовирусные соединения
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
JP6096324B2 (ja) 2013-01-23 2017-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス性トリアゾール誘導体
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
KR20150114566A (ko) 2013-03-05 2015-10-12 에프. 호프만-라 로슈 아게 항바이러스 화합물
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
AU2014265293B2 (en) 2013-05-16 2019-07-18 Riboscience Llc 4'-Fluoro-2'-methyl substituted nucleoside derivatives
SG11201509427RA (en) 2013-05-16 2015-12-30 Riboscience Llc 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
CA2929436C (en) 2013-11-27 2021-06-15 Euroscreen Sa Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EP3684374A4 (de) 2017-09-21 2021-06-16 Riboscience LLC 4'-fluor-2'-methyl-substituierte nukleosidderivate als hemmer der hcv-rna-replikation
CN109678814B (zh) * 2018-12-28 2021-03-23 浙江外国语学院 一种制备2-氯-1, 3-噻唑-5-甲醛的方法
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395007B (de) * 1990-03-29 1992-08-25 Noe Christian Modifizierte cyclische aminosaeuren und aus diesen synthetisierte dipeptide und verfahren zu ihrer herstellung
EP0630241A1 (de) * 1992-03-20 1994-12-28 The Wellcome Foundation Limited Indolderivate mit antiviraler wirkung
EP1315698A1 (de) * 1998-04-23 2003-06-04 Abbott Laboratories Pyrrolidine als neuraminidasehemmer
US6455571B1 (en) * 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases

Also Published As

Publication number Publication date
WO2003037895A1 (en) 2003-05-08
TW200302823A (en) 2003-08-16
DE60221875T2 (de) 2007-12-20
JP2005515172A (ja) 2005-05-26
ES2289161T3 (es) 2008-02-01
US7259163B2 (en) 2007-08-21
ATE370137T1 (de) 2007-09-15
EP1440069B1 (de) 2007-08-15
EP1440069A1 (de) 2004-07-28
AR037182A1 (es) 2004-10-27
US20050043390A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
DE60221875D1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60317466D1 (de) Nicotinamid-derivate als pde4-hemmer
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE529421T1 (de) Chinolinderivate als phosphodiesterase-hemmer
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
ATE506104T1 (de) Hepatitis-c-virus-hemmer
ATE368651T1 (de) Pyridazinon-derivate als gsk-3beta-hemmer
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DE60226775D1 (de) Azaindolylalkylaminderivate als 5-hydroxytryptamin-6-liganden
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE292115T1 (de) Indolderivate als cox-ii-inhibitoren
DE60120940D1 (de) Pyrrolidin-derivate verwendbar als bax-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition